Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
EIEiger BioPharmaceuticals, Inc. logo

Eiger BioPharmaceuticals, Inc. (EIGRQ)

Other OTC · Currency in USD
$8.50 ▲ +0.50 (+6.25%)
At close: Sep 19, 11:29 AM ET. Market closed.

Summary

Previous Close
$8.00
Open
$8.00
Day's Range
$8.00 – $8.50
52 Week Range
$1.10 – $16.00
Volume
725
Avg. Volume
8,258
Market Cap
$12.59M
Beta (5Y Monthly)
2.78
PE Ratio (TTM)
--
EPS (TTM)
-$50.78
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Eiger BioPharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
25
CEO
David Apelian

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical firm dedicated to discovering and advancing treatments for critical health issues, particularly hepatitis delta virus (HDV), among other severe diseases. The company's marketed product, Zokinvy, is prescribed for patients suffering from Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its development pipeline includes several key candidates: Lonafarnib: An orally administered farnesylation inhibitor that has successfully concluded Phase 3 clinical trials for HDV infection.

Earnings

DateEst.Actual
Apr 8, 2024-$7.50-$49.39Miss
Mar 14, 2024-$7.50-$49.39Miss
Dec 28, 2023-$9.71-$12.30Miss
Jun 30, 2023-$11.70-$14.02Miss
Mar 31, 2023-$13.59-$15.48Miss
Dec 31, 2022-$15.90-$17.11Miss

Similar stocks

Get free alerts on EIGRQ and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.